China SXT Pharmaceuticals, Inc. (SXTC) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
China SXT Pharmaceuticals, Inc. (SXTC) Bundle
Discover the true potential of China SXT Pharmaceuticals, Inc. (SXTC) with our professional-grade DCF Calculator! Adjust key assumptions, explore various scenarios, and evaluate how changes affect the valuation of China SXT Pharmaceuticals, Inc. (SXTC) – all within a convenient Excel template.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.2 | 4.8 | 2.6 | 2.0 | 1.9 | 1.5 | 1.2 | 1.0 | .8 | .6 |
| Revenue Growth, % | 0 | -7.45 | -45.53 | -24.23 | -2.19 | -19.85 | -19.85 | -19.85 | -19.85 | -19.85 |
| EBITDA | -1.0 | -1.9 | -5.1 | -5.2 | -2.4 | -1.1 | -.9 | -.7 | -.6 | -.5 |
| EBITDA, % | -19.55 | -38.76 | -194.11 | -264.13 | -121.91 | -71.66 | -71.66 | -71.66 | -71.66 | -71.66 |
| Depreciation | .3 | .3 | .3 | .3 | .2 | .2 | .1 | .1 | .1 | .1 |
| Depreciation, % | 6.43 | 7.23 | 12.3 | 12.69 | 10.54 | 9.84 | 9.84 | 9.84 | 9.84 | 9.84 |
| EBIT | -1.3 | -2.2 | -5.4 | -5.5 | -2.6 | -1.1 | -.9 | -.7 | -.6 | -.5 |
| EBIT, % | -25.98 | -45.99 | -206.41 | -276.82 | -132.45 | -74.39 | -74.39 | -74.39 | -74.39 | -74.39 |
| Total Cash | 7.3 | 13.3 | 15.5 | 17.4 | 12.1 | 1.5 | 1.2 | 1.0 | .8 | .6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 10.6 | 7.8 | 4.9 | 1.3 | 1.3 | 1.4 | 1.1 | .9 | .7 | .6 |
| Account Receivables, % | 206.25 | 162.57 | 188.84 | 68.19 | 69.82 | 87.6 | 87.6 | 87.6 | 87.6 | 87.6 |
| Inventories | .9 | .9 | 1.0 | .5 | .8 | .4 | .4 | .3 | .2 | .2 |
| Inventories, % | 17.29 | 17.99 | 39.1 | 26.94 | 41.99 | 28.66 | 28.66 | 28.66 | 28.66 | 28.66 |
| Accounts Payable | 1.9 | 1.5 | 1.5 | 1.4 | 1.3 | .8 | .6 | .5 | .4 | .3 |
| Accounts Payable, % | 37.6 | 30.49 | 56.96 | 69.88 | 66.35 | 52.26 | 52.26 | 52.26 | 52.26 | 52.26 |
| Capital Expenditure | -.4 | -.1 | -.1 | -.1 | .0 | -.1 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -7.88 | -1.95 | -2.4 | -3.58 | -0.36624 | -3.24 | -3.24 | -3.24 | -3.24 | -3.24 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -1.3 | -2.1 | -5.7 | -5.5 | -2.6 | -1.1 | -.9 | -.7 | -.6 | -.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -11.0 | .6 | -2.7 | -1.3 | -2.7 | -1.1 | -.6 | -.5 | -.4 | -.3 |
| WACC, % | 19.1 | 18.09 | 19.28 | 19.28 | 19.28 | 19.01 | 19.01 | 19.01 | 19.01 | 19.01 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -2 | |||||||||
| Present Terminal Value | -1 | |||||||||
| Enterprise Value | -3 | |||||||||
| Net Debt | -9 | |||||||||
| Equity Value | 7 | |||||||||
| Diluted Shares Outstanding, MM | 1 | |||||||||
| Equity Value Per Share | 7.57 |
What You Will Get
- Real SXTC Financial Data: Pre-filled with China SXT Pharmaceuticals' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See China SXT Pharmaceuticals' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for China SXT Pharmaceuticals, Inc. (SXTC).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs for precise calculations.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit your analysis needs.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for China SXT Pharmaceuticals, Inc. (SXTC).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Download the Template: Gain immediate access to the Excel-based SXTC DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other key parameters.
- Instant Calculations: The model automatically recalculates China SXT Pharmaceuticals' intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Leverage the results to inform your investment or financial decisions.
Why Choose This Calculator for China SXT Pharmaceuticals, Inc. (SXTC)?
- Accurate Data: Utilize real financials from China SXT Pharmaceuticals for trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the effort of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: Easy-to-navigate design and comprehensive instructions make it accessible for all users.
Who Should Use This Product?
- Investors: Accurately assess China SXT Pharmaceuticals, Inc.'s (SXTC) fair value prior to making investment choices.
- CFOs: Utilize a high-quality DCF model for financial reporting and comprehensive analysis.
- Consultants: Efficiently customize the template for valuation reports tailored to clients.
- Entrepreneurs: Acquire knowledge about financial modeling practices employed by leading pharmaceutical firms.
- Educators: Implement it as a teaching resource to illustrate valuation techniques.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled China SXT Pharmaceuticals, Inc. (SXTC) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for China SXT Pharmaceuticals, Inc. (SXTC).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.